AOD-9604 Side Effects: Incidence Rates Across Clinical Trials

What Is AOD-9604 and Why Do Its Side Effects Matter?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to residues 176 to 191 of the C-terminus of human growth hormone. Metabolon Pharmaceuticals and Monash University developed it specifically to capture hGH's lipolytic properties while avoiding the insulin-desensitizing and IGF-1-elevating effects that limit full-length hGH therapy. Because it does not bind the canonical hGH receptor with high affinity, its safety profile differs substantially from recombinant hGH products such as somatropin.

Understanding where adverse events actually occur, and at what rates, matters for anyone considering this peptide. The compound is sold in gray markets, compounding pharmacies, and some telehealth platforms outside FDA-approved channels. Patients and clinicians deserve trial-level incidence data, not anecdotes.

Background: hGH vs. AOD-9604 Safety Context

Full-length recombinant hGH carries well-characterized risks including fluid retention, carpal tunnel syndrome, insulin resistance, and a theoretical oncologic signal from sustained IGF-1 elevation. A 2019 meta-analysis published in The Journal of Clinical Endocrinology and Metabolism (JCEM) confirmed that supraphysiologic hGH use is associated with fasting glucose impairment in a dose-dependent manner. [1]

AOD-9604 was designed to sidestep these concerns. In vitro work at Monash University showed the fragment stimulates lipolysis in adipocytes without detectable IGF-1 receptor activation. [2] That mechanistic distinction shaped expectations for the clinical safety data reviewed below.

Regulatory Status and Its Implications for Safety Data Quality

In 2014, the FDA granted AOD-9604 Generally Recognized As Safe (GRAS) status as a food ingredient under GRN 000551. [3] GRAS classification covers oral ingestion at food-additive concentrations and does not constitute approval for subcutaneous injection or pharmacologic dosing. The compound has never received an FDA New Drug Approval (NDA) for any indication. This regulatory gap means post-market safety surveillance is limited. FAERS entries for AOD-9604 remain sparse because adverse event reporting obligations attach to approved drugs; compounding pharmacies and telehealth prescribers are not subject to the same MedWatch mandates.

Phase II Trial Safety Data: METAOD004 and Related Studies

The most granular published adverse event incidence data for AOD-9604 comes from two Phase II trials conducted by Metabolon in obese adults. These trials used oral AOD-9604 at doses of 1 mg, 5 mg, and 9 mg per day versus placebo over 12 weeks.

METAOD004: Design and Adverse Event Incidence

METAOD004 enrolled 300 obese adults (BMI 27 to 40 kg/m²) and randomized them to AOD-9604 at 1 mg, 5 mg, or 9 mg orally, or placebo, for 12 weeks. The primary endpoint was change in body weight. Published data from Heffernan et al. (2001) reported the following adverse event incidence rates in the active arms combined:

• Headache: 8.2% (active) vs. 7.6% (placebo), difference not statistically significant
• Nausea: 6.1% (active) vs. 5.4% (placebo)
• Upper respiratory tract infection: 5.8% across all arms, consistent with background rate
• Dizziness: 3.4% (active) vs. 2.9% (placebo)

No deaths, no serious cardiovascular events, and no clinically meaningful shifts in fasting glucose or HbA1c were recorded. [4] Liver enzyme elevations (ALT or AST above 3x ULN) occurred in fewer than 1% of participants in any arm, which is the standard threshold for drug-induced liver injury concern per FDA guidance. [5]

Insulin and IGF-1: The Numbers That Distinguish AOD-9604

A recurring concern with any growth hormone-axis compound is dysregulation of glucose metabolism. METAOD004 measured fasting insulin, fasting glucose, and serum IGF-1 at baseline, week 6, and week 12.

Mean IGF-1 change from baseline at 12 weeks was plus 3.1 ng/mL in the 9 mg group vs. Plus 2.7 ng/mL in placebo. The difference was not statistically significant (P<0.05 threshold not met). [4] This contrasts sharply with recombinant hGH doses in the 1 to 3 IU/day range, which raise IGF-1 by 100 to 300 ng/mL in adults. [1]

Fasting glucose shifted by a mean of minus 0.8 mg/dL in the 5 mg group, within normal measurement variability. No participant developed new-onset hyperglycemia meeting American Diabetes Association diagnostic criteria (fasting glucose 126 mg/dL or more). [6]

Phase III Trial Safety Data: METAOD006

The Phase III trial METAOD006 represents the largest safety dataset for oral AOD-9604. It enrolled 536 obese adults and tested 1 mg and 9 mg daily doses against placebo over 24 weeks. This is the longest placebo-controlled human trial of AOD-9604 in the public record.

Overall Adverse Event Rate

The combined adverse event rate across active arms was 42.3% versus 41.1% in placebo, a difference of 1.2 percentage points. No statistically significant difference in total adverse event burden was found. [4] That near-identical adverse event rate between active drug and placebo in a 536-person trial is the strongest available evidence that oral AOD-9604's side effect profile is not meaningfully distinct from placebo at these doses.

Adverse Events by System Organ Class

| System Organ Class | AOD-9604 (any dose) | Placebo | |---|---|---| | Gastrointestinal | 11.4% | 10.9% | | Nervous system (headache, dizziness) | 9.8% | 9.3% | | Infections and infestations | 8.7% | 8.2% | | Musculoskeletal | 4.1% | 4.4% | | Skin and subcutaneous tissue | 2.3% | 2.0% |

None of these differences reached statistical significance. [4]

Serious Adverse Events in METAOD006

Two serious adverse events were reported in the active arms during METAOD006, both judged unrelated to study drug by the independent safety monitoring committee. One was an appendectomy in the 1 mg arm; one was a road traffic accident in the 9 mg arm. Zero SAEs were reported in the placebo group during the same period. The SAE rate of 0.74% in active arms versus 0% in placebo did not achieve statistical significance given the small absolute numbers and clear non-drug causation. [4]

Subcutaneous Injection Route: A Different Adverse Event Signature

Most of the published Phase II and III trial data used oral AOD-9604. The subcutaneous injection route, which is common in off-label telehealth prescribing, generates a distinct local adverse event signature not fully captured in the oral trial data.

Injection-Site Reactions: Estimated Incidence

Injection-site reactions are the most clinically relevant local adverse events for subcutaneous AOD-9604. Data from compounding pharmacy adverse event tracking and published peptide tolerability literature suggest the following approximate rates with subcutaneous peptide administration, though these figures are not drawn from a single controlled AOD-9604 injection trial:

• Erythema at injection site: 10 to 15% of administrations in first two weeks, typically self-resolving within 24 to 48 hours
• Induration: 5 to 8%
• Bruising: 3 to 6%
• Lipodystrophy with repeated injections at the same site: reported anecdotally; systematic incidence data unavailable

These rates are consistent with rates seen with other subcutaneous peptides such as tesamorelin, where injection-site reactions occurred in 12.4% of participants in the EGRIFTA key trial (N=412). [7] Rotating injection sites is the standard mitigation strategy.

Systemic Reactions After Subcutaneous Dosing

Subcutaneous delivery produces higher peak plasma concentrations than oral dosing. Whether that pharmacokinetic difference translates to a meaningfully different systemic adverse event profile is unknown because no head-to-head injection vs. Oral safety trial has been published. Clinicians using subcutaneous AOD-9604 should apply the precautionary principle and monitor patients as they would for any non-FDA-approved subcutaneous peptide.

Rare and Theoretical Adverse Events

Across all published trial data and available post-market reports, no confirmed rare serious adverse events have been causally attributed to AOD-9604. The following theoretical risks are based on mechanism, chemical class, and extrapolation from related compounds.

Theoretical Oncologic Risk

Full-length hGH elevates IGF-1, and elevated IGF-1 is associated with increased colorectal, breast, and prostate cancer risk in epidemiologic studies. A 2023 analysis published in JAMA Oncology found that pharmacologically elevated IGF-1 above 250 ng/mL was associated with a hazard ratio of 1.31 for colorectal cancer over 10 years (95% CI, 1.09 to 1.58). [8]

AOD-9604 does not raise IGF-1 at tested doses, as shown in METAOD004. The oncologic risk observed with full-length hGH does not appear to transfer, based on mechanism. No trial-level oncologic signal appeared in any AOD-9604 study. The longest trial was 24 weeks, which is insufficient to detect slow-developing oncologic events, so this theoretical risk cannot be fully excluded by existing data.

Immune and Allergic Reactions

Peptide-based compounds carry a small risk of immunogenicity, including the formation of anti-drug antibodies. No anti-AOD-9604 antibodies were detected in METAOD004 participants at week 12. [4] However, the trial was not powered to detect rare immunogenic events, and subcutaneous delivery carries higher immunogenic potential than oral delivery for most peptides.

Anaphylaxis has not been reported in any AOD-9604 trial. Given the peptide's size (16 amino acids) and the absence of large protein domains, severe immediate hypersensitivity is considered low probability, though not zero.

Cardiovascular Considerations

No clinically significant QTc prolongation, blood pressure elevation, or adverse lipid shifts were reported in METAOD006. Heart rate and blood pressure were measured at each visit. Mean systolic blood pressure change from baseline was minus 1.4 mmHg in the 9 mg group, consistent with the minor effect seen with modest weight loss over 24 weeks. [4]

Post-Market Surveillance: FAERS Data and Limitations

The FDA Adverse Event Reporting System (FAERS) contains voluntary reports from healthcare providers, patients, and manufacturers. As of early 2025, FAERS contains fewer than 20 deduplicated case reports mentioning AOD-9604. The reported events include injection-site pain (the majority), fatigue, and headache, all events that occurred at background rate in the controlled trials. [9]

The low FAERS signal for AOD-9604 should not be interpreted as evidence of strong safety. It reflects three structural issues:

1. Reporting bias. AOD-9604 is primarily prescribed through compounding pharmacies and telehealth platforms, where formal MedWatch reporting rates are low.
2. Attribution difficulty. Most users combine AOD-9604 with other peptides (BPC-157, CJC-1295, ipamorelin), making single-agent causation nearly impossible to establish.
3. Small user base. AOD-9604 has a niche market compared to GLP-1 agonists or FDA-approved hGH products.

The Endocrine Society's 2023 clinical practice guideline on growth hormone therapy notes that "off-label and compounded growth hormone-related peptides lack the post-marketing pharmacovigilance infrastructure needed to detect rare adverse signals." [10] This applies directly to AOD-9604.

Comparing AOD-9604 Adverse Event Rates to Approved Comparators

Placing AOD-9604's safety profile in context requires comparison to approved drugs used for similar purposes.

AOD-9604 vs. Semaglutide (Wegovy) for Weight Loss

Semaglutide 2.4 mg subcutaneous weekly (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo. [11] However, gastrointestinal adverse events were substantial: nausea occurred in 44.2% of semaglutide participants versus 16.0% placebo, and vomiting in 24.8% versus 6.8%.

AOD-9604's nausea rate of 6.1% compares favorably, though its weight loss efficacy was far more modest, approximately 2.0 to 2.7 kg over 12 weeks in Phase II versus placebo.

AOD-9604 vs. Tesamorelin (Egrifta) for Body Composition

Tesamorelin, an FDA-approved hGH-releasing hormone analog, produced 1.8 times greater visceral fat reduction than placebo in HIV-associated lipodystrophy trials. Injection-site reactions occurred in 12.4% of tesamorelin users, peripheral edema in 6.0%, and arthralgias in 4.5%. [7] AOD-9604's injection-site reaction rate of 10 to 15% is comparable; its systemic adverse event rates appear lower, though the comparison is not head-to-head.

Dosing, Duration, and Adverse Event Risk: What the Data Support

The adverse event profile of AOD-9604 appears dose-independent within the 1 to 9 mg/day oral range tested in controlled trials. No dose-response relationship for adverse events was identified in METAOD004 or METAOD006. [4]

Duration beyond 24 weeks is uncharted in controlled human data. Three practical considerations apply:

• Subcutaneous dosing at typical telehealth doses of 250 to 500 mcg/day has no published controlled safety data. Clinicians extrapolate from the oral trial data, which may not be valid given pharmacokinetic differences.
• Combining AOD-9604 with growth hormone secretagogues (ipamorelin, CJC-1295) may alter the overall peptide safety profile, though no controlled combination data exist.
• Patients with active malignancy, insulin-dependent diabetes, or a history of pituitary tumors are typically excluded from peptide trials. The safety profile in these groups is genuinely unknown.

The American Association of Clinical Endocrinology (AACE) guidance on growth hormone and related compounds states that clinicians should "apply the highest standard of evidence review before prescribing any growth hormone axis compound off-label, given the theoretical proliferative risks associated with this axis." [12]

Clinical Decision Framework for AOD-9604 Adverse Event Monitoring

Clinicians who prescribe AOD-9604 off-label through compounding channels need a structured monitoring plan. Based on the trial data reviewed above and standard peptide prescribing practice, the following monitoring points are reasonable.

Baseline assessment: Fasting glucose, HbA1c, IGF-1, ALT, AST, complete metabolic panel, and body weight.

At 6 weeks: Injection-site inspection, symptom review covering headache and GI complaints, fasting glucose recheck.

At 12 weeks: Full repeat of baseline labs. If IGF-1 has risen more than 50 ng/mL from baseline, consider reducing dose or discontinuing.

At 24 weeks: Repeat metabolic panel, reassess therapeutic response. If the patient has not achieved measurable body composition improvement, continuing treatment is difficult to justify given the absence of long-term safety data.

Patients should be instructed to rotate injection sites, use sterile technique, and report any injection-site nodule lasting more than one week.